Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07549646 · ClinicalTrials.gov registry record · Phase 2
24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs
A Phase 2 study, sponsored by Children's Hospital of Philadelphia.
- Active
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT07549646 is a Phase 2 study that is active but no longer recruiting, run by Children's Hospital of Philadelphia. The registered enrollment target is 45 participants.
The verdict
NCT07549646, a Phase 2 study, is active but no longer recruiting, sponsored by Children's Hospital of Philadelphia.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effectiveness and safety of Trametinib (the "Study Drug") in patients with Ras/MAPK pathway driven vascular anomalies (VA). Trametinib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. Its use in this study is considered experimental because the FDA has not approved the study drug for treating people with VAs. The study will enroll participants 2 months of age up to 30 years of age that have been diagnosed with Ras/MAPK pathway driven vascular anomalies. Study participation will last up to 3 years and will involve regular study visits to Children's Hospital of Philadelphia (CHOP) Philadelphia Campus. Participants will need to take the study drug Trametinib for at least 2 years, or up to 3 years in total, if there is a positive response. Participating in this research means you will attend up to 16 clinic visits. Most visits will take approximately 30 minutes, but some visits will take approximately 2 hours, because you will be asked to complete questionnaires about your experience. Participating in this research also means taking the study drug, having pictures taken, and completing study drug diaries. There is also an optional portion to this study that involves collecting blood for biomarker testing.
Interventions
- DRUG Trametinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-08-27 |
| Est. Completion | 2030-08-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07549646
The ClinicalTrials.gov registry entry for NCT07549646 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trametinib is the first listed.
NCT07549646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07549646 about?
NCT07549646 is a clinical study titled "24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs". The purpose of this study is to assess the effectiveness and safety of Trametinib (the "Study Drug") in patients with Ras/MAPK pathway driven vascular anomalies (VA). Trametinib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. Its use in this...
What is the current status of trial NCT07549646?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-08-27. Estimated completion is 2030-08-27.
What interventions are being tested in trial NCT07549646?
The interventions under investigation include: Trametinib (DRUG).
Who is sponsoring clinical trial NCT07549646?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.